Boehringer Ingelheim and MiNA Therapeutics to Develop Novel Treatment Approaches for Fibrotic Liver Diseases
Boehringer Ingelheim and MiNA Therapeutics (“MiNA”), a pioneer in RNA activation therapeutics, today announced that they have signed a collaboration and licensing agreement focused on the development of novel compounds to treat fibrotic liver diseases such as NASH, based on MiNA’s small activating RNA (“saRNA”) therapeutics platform. The new partnership underscores Boehringer Ingelheim’s commitment to advancing innovative new treatment approaches and furthering its comprehensive clinical offerings in cardiometabolic diseases. It combines MiNA’s leading expertise in the development of saRNAs with Boehringer Ingelheim’s experience in bringing first-in-class breakthrough treatments to patients with cardiometabolic disease.
NASH is a major cause of liver fibrosis and cirrhosis and an area of high unmet medical need. It has an especially high prevalence among obese and diabetic patients and currently there are no treatments available. NASH is expected to become the most common cause of advanced liver disorders eventually necessitating liver transplantation in the coming decades.
saRNAs have been demonstrated to activate transcription of specific genes resulting in upregulation of proteins with therapeutic potential. In the new collaboration, Boehringer Ingelheim and MiNA aim to identify targets to restore metabolic functionality of hepatocytes and prevent fibrotic tissue formation in patients with NASH. It will enable Boehringer Ingelheim to rapidly design, profile and develop novel compounds, potentially also creating opportunities for combination with Boehringer Ingelheim’s other NASH-pipeline assets.
“This collaboration is a recognition of our platform and expertise in liver-based diseases as well as validation from an established pharmaceutical leader in what has been an exciting year for the company,” said Robert Habib, CEO of MiNA.
“This new collaboration is another sign of our ongoing commitment to patients with cardio-metabolic diseases, including NASH,” said Clive R. Wood, Ph.D., Corporate Senior Vice President Discovery Research at Boehringer Ingelheim. “It will combine MiNA’s pioneering work with saRNAs with our expertise in biopharmaceutical research and development,” added Wood.
Boehringer Ingelheim has a long history of excellence in the discovery and development of medicines for cardiometabolic disease patients. It has established a broad portfolio of marketed products for thromboembolic diseases, type 2 diabetes, acute myocardial infarction, hypertension and cardio-renal risk reduction. The cardiometabolic diseases pipeline extends beyond type 2 diabetes and anticoagulation with a focus on innovative drugs for the treatment of the devastating consequences of diabetes as well as contributing factors like obesity.
Under the terms of the agreement, MiNA will receive an upfront payment and committed research funding as well as potential research, development and regulatory milestone payments totalling up to EUR 307 million. In addition, MiNA is entitled to up to double-digit royalties on sales of selected products resulting from the partnership. No further financial details have been disclosed.
In this agreement, MiNA was advised by Ferghana Partners and Taylor Wessing LLP.
Please click on the link below for ‘Notes to Editors’:
Contact for MiNA Therapeutics:
Dr. Stephanie May
MacDougall Biomedical Communications
P: +49 89 2424 3494 :: M: +49 175 571 1562
Contacts for Boehringer Ingelheim:
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim GmbH
P: +49 6132 77-90815 :: M: + 49 151 150 20 690
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim Pharmaceuticals, Inc.
P: +1 203 791-6672 :: M: +1 203-957 5114
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
ABB Publishes 2017 Annual Report23.2.2018 08:59 | Tiedote
ABB Ltd has published its 2017 annual report on its website and has filed the annual report on Form 20-F with the United States Securities and Exchange Commission. The 2017 annual report is now available electronically at www.abb.com/groupreports. It provides comprehensive information on the company and its strategy, business, governance and financial performance. Shareholders may request a printed copy of the annual report via this link. It will be distributed when it becomes available later this month. ABB (ABBN: SIX Swiss Ex) is a pioneering technology leader in electrification products, robotics and motion, industrial automation and power grids, serving customers in utilities, industry and transport & infrastructure globally. Continuing a history of innovation spanning more than 130 years, ABB today is writing the future of industrial digitalization with two clear value propositions: bringing electricity from any power plant to any plug and automating industries from natural resour
Gilead Sciences Announces Senior Management Change23.2.2018 01:00 | Tiedote
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that James Meyers, Executive Vice President, Commercial Operations, will retire. Mr. Meyers joined Gilead in 1996 as a regional sales director and was appointed to his current role in 2016. Following a brief family leave earlier this year, Mr. Meyers made the decision to retire from his full-time role effective immediately. Mr. Meyers will remain with the company in an advisory capacity, to consult on priority projects and to assist with identifying his successor and facilitating the transition. The company will begin a search for his successor in the coming weeks. “Jim has been instrumental in leading Gilead through a period of tremendous growth and change, and he has built an exceptional team. I am confident in the ability of that team to execute against our ambitious goals and grateful to Jim for his commitment to assist us through this transition,” said John Milligan, PhD, President and Chief Executive Officer, Gilead Sciences. “
Trump International Hotel Washington, D.C. Announced as First Forbes Five Star Hotel in Downtown Washington, D.C.22.2.2018 22:21 | Tiedote
Trump International Hotel Washington, D.C. announces today that it has been awarded the 2018 Forbes Five-Star recognition, making it the first hotel to receive the prestigious distinction in Downtown Washington D.C. Forbes Travel Guide, the global authority on luxury travel, sends anonymous professional inspectors around the world to assess hotels, restaurants and spas against up to 800 objective standards focused on service and facilities. Just opened a short fifteen months ago, the property is located on Pennsylvania Avenue in the center of the city at the site of the Old Post Office. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222006277/en/ Trump International Hotel Washington, D.C. (Photo: Business Wire) Mickael Damelincourt, Managing Director, oversaw the recruitment and selection of the executives whose teams would lead the hotel through the construction and opening phases, instilling a commitment to the highest l
Entrust Datacard and Infineon Partner to Reduce Complexities with Securing IoT Deployments22.2.2018 21:30 | Tiedote
Entrust Datacard, a leading provider of trusted identity and secure transaction technology solutions, today announced it has joined the Infineon Security Partner Network (ISPN). The ISPN is part of Infineon Technologies AG, a leading provider of semiconductor solutions used in automotive, industrial, computing and Internet of Things applications. The ISPN is composed of associated and preferred security partners who are proven experts in security consulting, security solution provisioning, electronic design, systems integration and trust services management. The new partnership will apply the Entrust Datacard™ ioTrust™ Security Solution that uses identity-based technology to help securely connect the people, applications and devices that power the connected world. The tiered software uses sophisticated cryptographic technology to provide identity issuance, management and data security of connected things within industrial environments. As a global leader in Trusted Platform Modules (TP
Blue Danube Systems Joins xRAN Forum as a Massive MIMO System Supplier Fully Committed to Open Interfaces22.2.2018 21:10 | Tiedote
Blue Danube Systems, a provider of intelligent wireless access solutions that help mobile operators address the challenge of explosive data growth, today announced that it has joined the xRAN Forum (www.xran.org). The xRAN Forum was formed by several leading global mobile operators to develop, standardize and promote an open alternative to the traditionally closed, hardware-based RAN (Radio Access Network) architecture. Massive MIMO systems are widely recognized to be a critical element of future 5G wireless networks. Blue Danube’s unique approach to Massive MIMO, based on the company’s underlying High Definition Active Antenna Systems (HDAAS™) technology, not only delivers capacity gains in existing LTE networks with today’s smartphones but also enables intelligent analytics-based RF virtualization for multi-site network performance optimization. Blue Danube’s first Massive MIMO product, the BeamCraft™ 500, has been deployed at four FDD-LTE operators to date, interfacing to four diffe
Blue Danube Systems First to Demonstrate Benefits of FDD Massive MIMO in Clustered Multi-Sector Deployments22.2.2018 21:07 | Tiedote
Blue Danube Systems, a provider of intelligent wireless access solutions that help mobile operators address the challenge of explosive data growth, today announced it has successfully expanded the commercial deployment of its massive MIMO solution to multiple clustered cell sites, demonstrating total capacity improvements for directly adjoining sectors on existing LTE networks using current smartphones. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222006158/en/ Blue Danube Systems First to Demonstrate Benefits of FDD Massive MIMO in Clustered Multi-Sector Deployments (Photo: Business Wire) Despite the prevalent view that Massive MIMO systems will be central to 5G networks, it has not been clearly proven that the technology is deployable beyond isolated high-demand sectors where effects such as adjacent cell interference must be addressed. In fact, common digital-only Massive MIMO implementations typically operate as clos
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme